Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix Posts 10-Percent Rise in Q2 Revenue as Loss Swings to a Profit

NEW YORK (GenomeWeb News) — Affymetrix today said second-quarter revenue rose 10 percent, R&D costs dropped 10 percent, and a net loss swung to a small profit.
 
Total revenue for the three months ended June 30 rose to $88.3 million from $80.1 million year over year.
 
For the quarter, Affy said product revenue increased about 5 percent to $64 million; product-related revenue rose 21 percent to $17.2 million; royalties and other revenue rose 12.5 percent to $2.7 million; and revenue from Perlegen Sciences doubled to $4.4 million.  
 
The company said GeneChip consumable revenue was $67.2 million, consisting of array revenue of $41.0 million, reagent revenue of $14.2 million, and genotyping services revenue of $7.6 million. Instrument revenue was $8.8 million for the quarter.
 
“We are pleased with the sequential and year-over-year top-line revenue growth driven by the strong adoption of our new SNP 6.0 genotyping product," Kevin King, Affy’s Life Sciences’ president, said in a statement. "The successful launch of this product [in May] has resulted in a number of important new global commercial agreements.”
 
R&D spending slipped to $19.4 million from $21.6 million in the prior-year period.
 
The company posted a $1.2 million profit from a loss of $10 million year over year.
 
As of June 30, Affy had $232 million in cash, cash equivalents, and short-term investments.
 
The company said it expects total 2007 revenue in the range of $365 million to $385 million.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.